knowledge -WSS

knowledge

author：comprehensive 2025-08-26 23:47:24 - browse：22938

Ionis Pharmaceuticals, a California biotech that has spearheaded the development of RNA-targeting medicines, announced on Tuesday that its drug against familial chylomicronemia syndrome, a rare and serious disease that prevents the body from breaking down fats, succeeded in a late-stage clinical trial.

The Phase 3 trial, dubbed Balance, enrolled 66 adults who were randomly divided into three groups and given a monthly injection of placebo or one of two doses of olezarsen, the company’s experimental drug. Treatment with the higher dose of the therapy significantly lowered triglycerides in the blood of those on the drug for six months compared to participants given placebo, though a lower dose did not have this effect. Participants on the high dose didn’t have any instances of painful inflammation of the pancreas, one of the disease’s most serious symptoms, while there were 11 such episodes among those on placebo.

Researchers reported that the treatment was also generally safe, with fewer adverse events among those on olezarsen than among the placebo group.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： Key lawmaker blasts Congress’ efforts on addiction: ‘Shame on us’

WSS

2 US Navy sailors arrested for allegedly spying for China

Humana, CVS hope to turn members into patients at clinics

Why Congress must ban federal programs from using QALYs

I learned firsthand about improving diversity in clinical trials

My superpower is killing ticks

Awakening the world to the whoosh: A patient's crusade

entertainment

knowledge

leisure time

Tori Bowie and the unacceptable rates of Black maternal death

Trump drops motion seeking removal of DA probing efforts to overturn 2020 election in Georgia

Hepatitis C has a cure — but many Americans still lack access to it

What Henrietta Lacks settlement says about racism in medicine

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Indian pharmaceutical industry in denial over drug

Duchenne breakthrough therapy leaves behind pioneering families

Stem cell clinics for heart failure: buyer be wary

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

My superpower is killing ticks

knowledge

Senate committee advances SCOTUS ethics bill after alleged justice misconduct

White House drug shortage group privately met with industry

Mega Millions jackpot rises to record $1.55 billion for Tuesday's drawing

Who is Magistrate Judge Moxila Upadhyaya in Trump's Jan. 6 case?

Divers poised to search for children washed away in Pennsylvania flash flood

Judge rejects Trump's request to move Stormy Daniels hush

entertainment

focus

leisure time

knowledge